29 results
Thumbnail

D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG

Thumbnail

D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population

Thumbnail

D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms

Thumbnail

D1.366 - “Intense peri-vaginal itching as a lone symptom”: a unique presentation of Progesterone (Progestogen) hypersensitivity (PH)

Thumbnail

D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab

Thumbnail

D1.369 - Immediate hypersensitivity to dostarlimab successfully managed with desensitization

Thumbnail

D1.370 - Desensitisation to low-dose acetylsalicylic acid in NERD. Clinical follow-up of aspirin therapy after desensitisation (ATAD)

Thumbnail

D1.371 - Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants

Thumbnail

D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity

Thumbnail

D1.375 - Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience

Thumbnail

D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide

Thumbnail

D1.377 - Folic Acid Allergy: A Rare Case

Thumbnail

D1.378 - Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial